- Compounding is a prescription and pharmacy pathway. It is distinct from the FDA approval pathway for a finished drug product.
- FDA says compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing.
- 503A and 503B describe different statutory pathways. Neither category is a product approval, quality grade, or safety ranking.
- Ask the licensed provider and dispensing pharmacy about the prescription, label, pharmacy identity, and instructions that apply to you.
What does “compounded” mean?
A compounded semaglutide preparation is made by a compounding pharmacy for a patient-specific prescription context. That pathway is distinct from the FDA review of an approved finished drug product. The preparation, label, dispensing pharmacy, and applicable oversight depend on the prescription and state requirements.
FDA explains that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before they are marketed. FDA also advises patients to obtain a prescription from a doctor and fill it at a state-licensed pharmacy. Those are regulatory and dispensing boundaries, not a judgment about a specific Kind MD prescription or pharmacy.
What FDA review does and does not mean
An FDA-approved drug product has gone through a product-specific review pathway that covers its submitted formulation, labeling, manufacturing information, and proposed uses. A compounded preparation is handled under a different legal framework. FDA’s page on unapproved GLP-1 drugs describes why patients should ask questions about the source and use a licensed prescriber and pharmacy.
FDA has also raised concerns about unapproved GLP-1 products, including mislabeled products and dosing errors. This page does not determine whether any particular preparation is lawful, safe, effective, or appropriate for you. A licensed healthcare provider makes an independent prescribing decision when clinically appropriate.
Where 503A and 503B fit
Section 503A generally applies to compounding by a licensed pharmacist in a state-licensed pharmacy or by a licensed physician, with a valid prescription for an identified patient. Section 503B applies to compounding in an outsourcing facility. The FDA’s statutory comparison describes different exemptions and requirements for each section.
Those labels describe a facility and legal pathway. They do not establish FDA approval of a compounded drug, accreditation, a quality ranking, or a conclusion that one preparation is safer than another. Kind MD works with a pharmacy network that includes both 503A compounding pharmacies and 503B outsourcing facilities; the dispensing pharmacy and applicable oversight may vary by prescription and state.
Questions to ask before filling a prescription
- Which licensed pharmacy will dispense this prescription, and what state oversight applies?
- What does the prescription label say about the preparation, directions, and contact information?
- Who should I contact if the label, packaging, or pharmacy information is unclear?
- What questions should I bring to my prescribing provider before treatment?
Do not use a blog to decide whether to start, stop, change, measure, store, or administer a medicine. Follow the actual prescription and the instructions from your licensed healthcare provider and dispensing pharmacy.
Kind MD is a telehealth platform that connects eligible patients with licensed healthcare providers who may prescribe compounded semaglutide or tirzepatide when clinically appropriate. Kind MD works with licensed U.S. pharmacies. The dispensing pharmacy and applicable oversight may vary by prescription and state.
Have questions about your care options?
Start with information for a licensed provider to review.
Take the Free Quiz →